US Patent Issued to Eli Lilly and Co., Board of Regents, The University of Texas System on Aug. 25 for "Combination therapy with a mutant IDH inhibitor and a Bcl-2 inhibitor" (Indiana, Texas Inventors)

ALEXANDRIA, Va., Aug. 25 -- United States Patent no. 12,714,712, issued on Aug. 25, was assigned to Eli Lilly and Co. (Indianapolis) and Board of Regents, The University of Texas System (Austin, Texas).

"Combination therapy with a mutant IDH inhibitor and a Bcl-2 inhibitor" was invented by Nathan Arthur Brooks (Fishers, Ind.), Courtney DiNardo (Houston), Raymond Gilmour (Indianapolis), Marina Konopleva (Houston) and Vivian Salama (Houston).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to combination therapy with a mutant IDH inhibitor of Formula (I) and Bcl-2 inhibitor, for the treatment of cancer."

The patent was filed on March 22, 2021, under Application No. 17/912,341.

*For...